IDEXX Laboratories (NASDAQ: IDXX) appoints Michael Erickson CEO in 2026
Rhea-AI Filing Summary
IDEXX Laboratories is planning a CEO transition. Jonathan (Jay) Mazelsky will step down as President and Chief Executive Officer on May 12, 2026 and become Executive Chair of the Board until his planned retirement following the annual shareholder meeting in May 2027. Michael (Mike) Erickson, PhD, currently Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine, will become President and CEO and join the Board as a Class II director on the same date.
Erickson’s CEO terms include a $1,000,000 annual base salary, an annual bonus targeted at 120% of base salary, and a 2026 long‑term equity incentive with a target grant value of at least $7.8 million split between stock options and performance RSUs. His amended change‑in‑control agreement provides cash severance of up to three times salary and average bonus plus benefit continuations and accelerated vesting on time‑based equity after a qualifying change‑in‑control termination. Mazelsky, as Executive Chair, will receive a $1,150,000 base salary and an incentive structure tied to 2026 performance and a time‑vesting RSU grant with a target value of at least $8.275 million.
Positive
- None.
Negative
- None.
Insights
Orderly CEO handoff with robust, standard large‑cap severance and equity terms.
The company is executing a planned CEO succession where Jonathan Mazelsky transitions from Chief Executive Officer to Executive Chair on May 12, 2026, with Michael Erickson, PhD, assuming the President and CEO role and joining the Board the same day. Mazelsky is expected to retire following the shareholder meeting in May 2027, which creates a defined overlap period intended to support continuity.
Erickson’s package—$1,000,000 base salary, a bonus target of 120% of salary, and at least $7.8 million in 2026 equity split between stock options and performance RSUs—aligns most of his upside with long‑term share performance. The amended change‑in‑control agreement offering a lump sum of three times salary plus average bonus, multi‑year benefit continuation, and full vesting of time‑based equity after a qualifying change‑in‑control termination follows typical market practice for senior CEOs in established issuers.
Mazelsky’s Executive Chair role includes a $1,150,000 base salary, a blended bonus target for 2026, and at least $8.275 million in time‑vesting RSUs covering 2026 and part of 2027. Investors evaluating governance may focus on how responsibilities are allocated between the new CEO, the Executive Chair, and the independent Lead Director after May 12, 2026, as well as future disclosures on performance goals tied to the performance RSUs.
8-K Event Classification
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
IDEXX LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) | ||
| of incorporation) |
(Address of principal executive offices) |
(ZIP Code) |
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
CEO Transition.
On January 11, 2026, Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) of his intent to step down as the Company’s President and Chief Executive Officer effective as of May 12, 2026 (the “Transition Date”) and retire from the Company and the Company’s Board of the Directors (the “Board”) immediately following the Company’s annual meeting of shareholders in May 2027 (the “Retirement Date”). On January 13, 2026, the Company announced that effective as of the Transition Date Mr. Mazelsky will transition to the role of Executive Chair of the Board and Michael (Mike) Erickson, PhD, will assume the role of President and Chief Executive Officer of the Company and join the Board as a Class II Director. In his capacity as President and Chief Executive Officer, Dr. Erickson will serve as the Company’s principal executive officer. Mr. Mazelsky will work closely with Dr. Erickson until Mr. Mazelsky’s Retirement Date to support a seamless transition. Mr. Lawrence D. Kingsley, currently serving as the Board’s independent Non-Executive Chair, will serve as independent Lead Director effective as of the Transition Date.
Dr. Erickson, 52, brings nearly two decades of leadership experience and significant healthcare technology and innovation expertise. Since joining IDEXX in 2011, he has held senior positions across key portions of the Company’s business, including diagnostics, software, strategy and corporate accounts, and currently serves as Executive Vice President and General Manager of IDEXX’s Global Point of Care Diagnostics and Telemedicine lines of business. Prior to joining the Company, Dr. Erickson advised leading pharmaceutical, biotechnology and health service companies as an Associate Principal at McKinsey & Company.
There are no arrangements or understandings between Dr. Erickson and any other persons pursuant to which he will be appointed to serve as the Company’s President and Chief Executive Officer. Dr. Erickson has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K, and Dr. Erickson has no family relationships with any director or executive officer of the Company.
Erickson Letter Agreement.
On January 12, 2026, in connection with Dr. Erickson’s anticipated appointment as President and Chief Executive Officer commencing on the Transition Date, Dr. Erickson entered into a letter agreement (the “Erickson Letter Agreement”) with the Company. The Erickson Letter Agreement sets forth the terms and conditions of Dr. Erickson’s employment as President and Chief Executive Officer and further provides that Dr. Erickson will be appointed to the Board as of the Transition Date and thereafter will be nominated by the Board for reelection during his employment as President and Chief Executive Officer.
Under the terms of the Erickson Letter Agreement, Dr. Erickson will receive an annualized base salary of $1,000,000 and an annual bonus with a target of 120% of base salary, effective as of the Transition Date. With respect to the Company’s 2026 fiscal year, Dr. Erickson is expected to receive a long-term incentive equity award with a target grant date value of not less than $7.8 million, to be granted in the form of stock options (50%) and performance restricted stock units (50%), under the Company’s 2018 Stock Incentive Plan (as amended, restated, amended and restated or replaced from time to time, the “Incentive Plan”), as part of the Company’s annual equity award cycle in February 2026. With respect to the Company’s 2027 fiscal year and each year thereafter during his employment as President and Chief Executive Officer, Dr. Erickson will be eligible to receive equity awards under the Incentive Plan, with grant date values and terms and conditions as determined by the Compensation and Talent Committee of the Board from time to time.
If Dr. Erickson’s employment is terminated by the Company following the Transition Date without “Cause” (as defined therein), other than under the terms of the Erickson CIC Agreement (as defined and described below), the Erickson Letter Agreement provides that Dr. Erickson will be entitled to receive the following, subject to execution and non-revocation of a release of claims and continued compliance with the applicable restrictive covenants:
| · | Salary continuation for two years following termination of employment; | |
| · | A lump-sum payment of the employer portion of the cost of continued health benefits for Dr. Erickson and covered dependents for such two-year period; and | |
| · | Continued vesting of equity incentive awards for two years following termination of employment, except as may be otherwise provided under the applicable award agreements. |
The Erickson Letter Agreement does not amend or supersede the terms of the Confidential Information, Work Product, and Restrictive Covenant Agreement, between Dr. Erickson and the Company, dated as of March 4, 2022, or any award agreements evidencing grants under the Company’s stock incentive plans to which Dr. Erickson is a party.
A copy of the Erickson Letter Agreement is included as Exhibit 10.1 to this Current Report on Form 8-K. The description of the Erickson Letter Agreement included in this Current Report on Form 8-K is a summary, is not complete and is qualified in its entirety by reference to the terms of the Erickson Letter Agreement filed as Exhibit 10.1 hereto.
Erickson Amended and Restated CIC Agreement.
As an Executive Vice President, Dr. Erickson was a party to a change in control agreement that provided for certain benefits upon a qualifying termination of employment that follows a change in control of IDEXX. In connection with the CEO transition, Dr. Erickson entered into an amended and restated change in control agreement (the “Erickson CIC Agreement”) on January 12, 2026, to be effective on the Transition Date.
Under the Erickson CIC Agreement, if Dr. Erickson’s employment is terminated after the Transition Date by the Company without “Cause” or by Dr. Erickson with “Good Reason” within the two-year period following a “Change in Control” (as such terms are defined in the Erickson CIC Agreement) (a “Qualifying CIC Termination”), Dr. Erickson will be entitled to receive the following, subject to execution and non-revocation of a release of claims and continued compliance with the applicable restrictive covenants:
| · | A lump-sum payment of an amount equal to the sum of (i) earned but unpaid base salary, (ii) target bonus for the portion of the year prior to the Qualifying CIC Termination, and (iii) any compensation previously deferred by Dr. Erickson and any accrued vacation pay, in each case to the extent unpaid; | |
| · | A lump-sum payment of an amount equal to three times the sum of (i) Dr. Erickson’s annual base salary and (ii) the average bonus received by him for the three prior full fiscal years; | |
| · | Continuation of all benefits under welfare, benefit, savings and retirement plans for up to three years; and | |
| · | Reimbursement of up to $12,500 per year (an aggregate of $25,000) for expenses incurred in connection with outplacement services and relocation costs in connection with obtaining new employment. |
In addition, the Erickson CIC Agreement provides that upon a Qualifying CIC Termination, all shares underlying Dr. Erickson’s outstanding equity awards subject only to time-based vesting conditions will become immediately exercisable or vested, as applicable. The terms of the performance-based equity awards will continue to be governed by the Incentive Plan and the applicable equity award agreements.
A copy of the Erickson CIC Agreement is included as Exhibit 10.2 to this Current Report on Form 8-K. The description of the Erickson CIC Agreement included in this Current Report on Form 8-K is a summary, is not complete and is qualified in its entirety by reference to the terms of the Erickson CIC Agreement filed as Exhibit 10.2 hereto.
Mazelsky Letter Agreement.
On January 12, 2026, Mr. Mazelsky entered into a letter agreement (the “Mazelsky Letter Agreement”) with the Company, which will become effective and supersede Mr. Mazelsky’s current employment agreement with the Company effective on the Transition Date. The Mazelsky Letter Agreement provides for the terms and conditions of his continued employment as Executive Chair from the Transition Date through the Retirement Date, unless terminated earlier by the Company or Mr. Mazelsky. The Mazelsky Letter Agreement provides that, in exchange for his service as Executive Chair, Mr. Mazelsky will be paid an annual base salary of $1,150,000 through the Retirement Date. In addition, with respect to the 2026 fiscal year, Mr. Mazelsky will be eligible for a target annual bonus opportunity determined as a percentage of the annual base salary actually paid with respect to the 2026 fiscal year equal to the blended rate of (i) 130% for the period from January 1 through the Transition Date and (ii) 100% for the period from the Transition Date through December 31, 2026 (the “FY 2026 Bonus”).
As part of the Company’s annual equity award cycle, it is expected that Mr. Mazelsky will receive a grant of time-vesting restricted stock units with a target grant date value of not less than $8.275 million in February 2026, which will serve as Mr. Mazelsky’s equity incentive compensation with respect to the Company’s 2026 fiscal year and with respect to the portion of the Company’s 2027 fiscal year prior to the Retirement Date. Mr. Mazelsky will not be eligible for any other cash or equity incentive payments with respect to his employment as Executive Chair during the 2027 fiscal year.
If Mr. Mazelsky’s employment with the Company is terminated by the Company after the Transition Date and prior to the Retirement Date without “Cause” (as defined in the Mazelsky Letter Agreement) (an “Involuntary Termination”), Mr. Mazelsky will be entitled to receive the following, subject to execution and non-revocation of a release of claims and continued compliance with the applicable restrictive covenants:
| · | A lump-sum payment of Mr. Mazelsky’s base salary through the Retirement Date; and | |
| · | FY 2026 Bonus (to the extent not already paid), calculated based on actual performance of the Company, payable at the same time such bonus is paid to other executive officers of the Company. |
If the Involuntary Termination occurs on or prior to February 14, 2027, the Company will permit Mr. Mazelsky to take a personal unpaid leave through February 15, 2027, at which time Mr. Mazelsky will be deemed to retire and will be treated as experiencing a qualifying “retirement” for purposes of the applicable compensation and benefit plans and programs of the Company.
The Mazelsky Letter Agreement does not amend or supersede the terms of the Confidential Information, Work Product, and Restrictive Covenant Agreement, between Mr. Mazelsky and the Company, dated as of January 19, 2022, or any award agreements evidencing grants under the Company’s stock incentive plans to which Mr. Mazelsky is a party.
A copy of the Mazelsky Letter Agreement is included as Exhibit 10.3 to this Current Report on Form 8-K. The description of the Mazelsky Letter Agreement included in this Current Report on Form 8-K is a summary, is not complete and is qualified in its entirety by reference to the terms of the Mazelsky Letter Agreement filed as Exhibit 10.3 hereto.
Item 7.01. Regulation FD Disclosure.
A copy of the press release dated January 13, 2026, announcing these matters is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits |
| 10.1 | Letter Agreement by and between Michael (Mike) Erickson, PhD, and IDEXX Laboratories, Inc., dated January 12, 2026. |
| 10.2 | Amended and Restated Change in Control Agreement by and between Michael (Mike) Erickson, PhD, and IDEXX Laboratories, Inc., dated January 12, 2026. |
| 10.3 | Letter Agreement by and between Jonathan (Jay) Mazelsky and IDEXX Laboratories, Inc., dated January 12, 2026. |
| 99.1 | Press Release issued by IDEXX Laboratories, Inc. on January 13, 2026. |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IDEXX LABORATORIES, INC. | ||
| Date: January 13, 2026 | By: | /s/ Sharon E. Underberg |
| Sharon E. Underberg | ||
| Executive Vice President, General Counsel and Corporate Secretary | ||
FAQ
What leadership change does IDEXX Laboratories (IDXX) disclose in this 8-K?
The company states that Jonathan (Jay) Mazelsky will step down as President and Chief Executive Officer on May 12, 2026, becoming Executive Chair, and that Michael (Mike) Erickson, PhD, will assume the role of President and Chief Executive Officer and join the Board as a Class II Director on the same date.
When is Jay Mazelsky expected to retire from IDEXX Laboratories (IDXX)?
The filing explains that Jay Mazelsky plans to retire from the company and its Board immediately following IDEXX Laboratories’ annual meeting of shareholders in May 2027, which is referred to as the Retirement Date.
What are Michael Erickson’s key compensation terms as the new CEO of IDEXX (IDXX)?
Upon becoming President and Chief Executive Officer, Michael Erickson will receive an annual base salary of $1,000,000, an annual bonus with a target of 120% of base salary, and for the 2026 fiscal year a long‑term equity incentive award with a target grant date value of at least $7.8 million, split equally between stock options and performance restricted stock units.
What change-in-control protections does Michael Erickson receive at IDEXX Laboratories?
Under the amended and restated change in control agreement, if Michael Erickson experiences a qualifying termination within two years following a change in control, he is entitled to lump‑sum payments including earned but unpaid salary and bonus, an additional lump‑sum of three times the sum of his annual base salary and average bonus for the prior three full fiscal years, continuation of benefits for up to three years, reimbursement of up to $25,000 in outplacement and relocation expenses, and full vesting of time‑based equity awards.
How will Jay Mazelsky be compensated as Executive Chair at IDEXX (IDXX)?
From the Transition Date through his Retirement Date, Jay Mazelsky will receive an annual base salary of $1,150,000. For 2026, he is eligible for a target annual bonus determined as a blended percentage of this salary and is expected to receive time‑vesting restricted stock units with a target grant date value of at least $8.275 million, covering the 2026 fiscal year and the part of 2027 before his retirement.
What severance could Jay Mazelsky receive if terminated before his planned retirement?
If the company terminates Jay Mazelsky without Cause after the Transition Date and before the Retirement Date, he is entitled to a lump‑sum payment of his base salary through the Retirement Date and payment of his 2026 blended bonus, based on actual company performance, when bonuses are paid to other executive officers.
Does IDEXX Laboratories (IDXX) mention an accompanying press release about the CEO transition?
Yes. The company notes that a press release dated January 13, 2026, announcing these leadership and compensation matters is furnished as Exhibit 99.1.